Scarica l'app Stockscreener
1.85
2.21%
0.04
Dopo l'orario di chiusura:
1.86
0.01
+0.54%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SAVA Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$1.81
Aprire:
$1.8
Volume 24 ore:
1.24M
Relative Volume:
0.91
Capitalizzazione di mercato:
$104.83M
Reddito:
-
Utile/perdita netta:
$-97.22M
Rapporto P/E:
-1.3406
EPS:
-1.38
Flusso di cassa netto:
$-82.44M
1 W Prestazione:
-4.64%
1M Prestazione:
-7.96%
6M Prestazione:
-21.61%
1 anno Prestazione:
-84.76%
Intervallo 1D:
$1.76
$1.90
Intervallo di 1 settimana:
$1.75
$1.95
Portata 52W:
$1.15
$42.20
Cassava Sciences Inc Stock (SAVA) Company Profile
Nome
Cassava Sciences Inc
Settore
Industria
Telefono
512-501-2444
Indirizzo
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Confronta SAVA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
1.85 | 104.83M | 0 | -97.22M | -82.44M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-10-08 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-07-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-11-16 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-07-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-07-07 | Reiterato | Maxim Group | Buy |
| 2021-04-27 | Iniziato | B. Riley Securities | Buy |
| 2021-02-16 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-05-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-15 | Downgrade | Maxim Group | Buy → Hold |
| 2020-01-10 | Reiterato | Maxim Group | Buy |
Mostra tutto
Cassava Sciences Inc Borsa (SAVA) Ultime notizie
Shareholders Filed a Lawsuit Against Cassava Sciences for Misleading Alzheimer’s Drug Claims - TradingView
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Cassava Sciences, Inc. Investors to Lead the Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. LawsuitSAVA - ACCESS Newswire
Cassava Sciences, Inc. (NASDAQ:SAVA) Shares Sold by Cetera Investment Advisers - Defense World
BNP Paribas Financial Markets Buys 55,813 Shares of Cassava Sciences, Inc. (NASDAQ:SAVA) - Defense World
Cassava Sciences, Inc. (NASDAQ:SAVA) Stake Lifted by Northern Trust Corp - Defense World
Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha
Cassava Sciences Holds 2025 Annual Meeting, Elects Directors - TipRanks
Transcript : Cassava Sciences, Inc.Shareholder/Analyst Call - marketscreener.com
Cassava Sciences, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationSAVA - ACCESS Newswire
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - ACCESS Newswire
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - ACCESS Newswire
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - ACCESS Newswire
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Class Action Filed Against Cassava Sciences, Inc. (SAVA)February 10, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Investors in Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - ACCESS Newswire
Cassava Reports Q1 2025 Financials Results, Provides Business Update - GlobeNewswire
Cassava Sciences Shifts Focus to TSC-Related Epilepsy - TipRanks
Cassava Sciences (SAVA) Faces Financial Challenges Amid Strategic Shifts - GuruFocus
Invesco Ltd. Trims Stock Position in Cassava Sciences, Inc. (NASDAQ:SAVA) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Cassava Sciences (SAVA) Appoints New SVP of Neuroscience | SAVA Stock News - GuruFocus
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC - citybiz
Investors who Lost Money on Cassava Sciences, Inc. (SAVA) Should Contact Levi & Korsinsky About Pending Class ActionSAVA - ACCESS Newswire
Cassava Sciences Inc Azioni (SAVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cassava Sciences Inc Azioni (SAVA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Option Exercise |
1.18 |
50,000 |
59,000 |
71,300 |
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.86 |
59,800 |
230,828 |
11,500 |
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.82 |
2,000 |
7,640 |
0 |
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):